PE20091109A1 - Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c - Google Patents
Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis cInfo
- Publication number
- PE20091109A1 PE20091109A1 PE2008002086A PE2008002086A PE20091109A1 PE 20091109 A1 PE20091109 A1 PE 20091109A1 PE 2008002086 A PE2008002086 A PE 2008002086A PE 2008002086 A PE2008002086 A PE 2008002086A PE 20091109 A1 PE20091109 A1 PE 20091109A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- hepatitis
- virus
- humanized antibody
- antibody against
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US606607P | 2007-12-17 | 2007-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091109A1 true PE20091109A1 (es) | 2009-08-12 |
Family
ID=40801628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008002086A PE20091109A1 (es) | 2007-12-17 | 2008-12-17 | Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c |
Country Status (18)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12010987B2 (en) | 2004-10-07 | 2024-06-18 | Transmedics, Inc. | Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status |
| CA2985229C (en) | 2004-10-07 | 2023-02-07 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
| US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
| US9457179B2 (en) | 2007-03-20 | 2016-10-04 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
| US9814230B2 (en) | 2008-01-31 | 2017-11-14 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
| MX2011006516A (es) * | 2008-12-17 | 2011-08-04 | Genentech Inc | Terapia de combinacion de virus de hepatitis c. |
| WO2012142487A1 (en) | 2011-04-14 | 2012-10-18 | Transmedics, Inc. | Organ care solution for ex-vivo machine perfusion of donor lungs |
| JP6158171B2 (ja) * | 2011-05-02 | 2017-07-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 合成ｃ型肝炎ゲノム、並びに、その製造方法及びその使用 |
| US20130084301A1 (en) * | 2011-08-30 | 2013-04-04 | Steven Foung | Cluster of Neutralizing Antibodies to Hepatitis C Virus |
| US10215457B2 (en) * | 2011-12-09 | 2019-02-26 | Applied Materials, Inc. | Heat exchanger for cooling a heating tube and method thereof |
| ITFI20120122A1 (it) * | 2012-06-15 | 2013-12-16 | Kedrion S P A 50 | Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso. |
| CN102928595A (zh) * | 2012-10-12 | 2013-02-13 | 武汉康苑生物医药科技有限公司 | 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒 |
| WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
| SG10201802194WA (en) * | 2013-09-19 | 2018-05-30 | Novavax Inc | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| RU2539770C1 (ru) * | 2013-12-27 | 2015-01-27 | Татьяна Николаевна Власик | Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты) |
| EP3151663B1 (en) | 2014-06-02 | 2020-09-23 | Transmedics, Inc. | Ex vivo organ care system |
| GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
| BR112017010520B1 (pt) | 2014-12-12 | 2022-08-30 | Tevosol, Inc | Aparelho e método para perfusão de órgãos |
| CA2997267A1 (en) | 2015-09-09 | 2017-03-16 | Transmedics, Inc. | Aortic cannula for ex vivo organ care system |
| CN105177017B (zh) * | 2015-10-30 | 2020-06-02 | 中国人民解放军第三军医大学第一附属医院 | 抗多亚基因型hcv抗体基因r4-85及其应用 |
| CN105219780B (zh) * | 2015-10-30 | 2020-06-02 | 中国人民解放军第三军医大学第一附属医院 | 抗多亚基因型hcv抗体基因r3-19及其应用 |
| KR102640157B1 (ko) * | 2016-03-22 | 2024-02-27 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 인간화 항-클라우딘-1 항체 및 이의 용도 |
| DK3462861T5 (da) | 2016-05-30 | 2024-01-08 | Transmedics Inc | Fremgangsmåde til ex vivo-lungeventilati on med et varierende udvendigt tryk |
| US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2272443B (en) * | 1991-06-10 | 1995-10-25 | Lucky Ltd | Nucleotide and amino acid sequences of Korean hepatitis C virus |
| ITPN960013A1 (it) * | 1996-02-26 | 1997-08-26 | Marcello Piazza | Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc. |
| US20060188511A1 (en) | 1998-11-05 | 2006-08-24 | Foung Steven K | Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes |
| AU2002243259B2 (en) * | 2000-12-01 | 2008-02-07 | The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C |
| ITRM20020049A1 (it) * | 2002-01-30 | 2003-07-30 | Biostrands S R L | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
| CA2601400A1 (en) * | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
-
2008
- 2008-12-17 EP EP08865543.6A patent/EP2231704B1/en not_active Not-in-force
- 2008-12-17 KR KR1020107015856A patent/KR20100102163A/ko not_active Ceased
- 2008-12-17 CN CN200880125928.5A patent/CN101939334B/zh not_active Expired - Fee Related
- 2008-12-17 BR BRPI0821252-0A patent/BRPI0821252A2/pt not_active IP Right Cessation
- 2008-12-17 US US12/809,050 patent/US9193781B2/en not_active Expired - Fee Related
- 2008-12-17 MX MX2010006767A patent/MX2010006767A/es not_active Application Discontinuation
- 2008-12-17 CA CA2708740A patent/CA2708740C/en not_active Expired - Fee Related
- 2008-12-17 AU AU2008341542A patent/AU2008341542B2/en not_active Ceased
- 2008-12-17 WO PCT/IB2008/003952 patent/WO2009081285A2/en not_active Ceased
- 2008-12-17 JP JP2010538953A patent/JP5763344B2/ja not_active Expired - Fee Related
- 2008-12-17 RU RU2010129429/10A patent/RU2462475C2/ru not_active IP Right Cessation
- 2008-12-17 PE PE2008002086A patent/PE20091109A1/es not_active Application Discontinuation
- 2008-12-17 NZ NZ585622A patent/NZ585622A/xx not_active IP Right Cessation
- 2008-12-17 CL CL2008003784A patent/CL2008003784A1/es unknown
- 2008-12-17 TW TW097149206A patent/TW200940090A/zh unknown
- 2008-12-18 AR ARP080105506A patent/AR072039A1/es not_active Application Discontinuation
-
2010
- 2010-05-16 IL IL205795A patent/IL205795A0/en unknown
- 2010-05-18 ZA ZA2010/03509A patent/ZA201003509B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2708740A1 (en) | 2009-07-02 |
| EP2231704A2 (en) | 2010-09-29 |
| MX2010006767A (es) | 2010-10-05 |
| RU2462475C2 (ru) | 2012-09-27 |
| JP2011505867A (ja) | 2011-03-03 |
| ZA201003509B (en) | 2011-12-28 |
| HK1144440A1 (en) | 2011-02-18 |
| US20110002926A1 (en) | 2011-01-06 |
| KR20100102163A (ko) | 2010-09-20 |
| WO2009081285A2 (en) | 2009-07-02 |
| BRPI0821252A2 (pt) | 2015-06-16 |
| CA2708740C (en) | 2017-07-18 |
| WO2009081285A3 (en) | 2010-08-26 |
| US9193781B2 (en) | 2015-11-24 |
| TW200940090A (en) | 2009-10-01 |
| AU2008341542A1 (en) | 2009-07-02 |
| CN101939334B (zh) | 2015-01-14 |
| EP2231704B1 (en) | 2015-08-12 |
| CN101939334A (zh) | 2011-01-05 |
| IL205795A0 (en) | 2010-11-30 |
| JP5763344B2 (ja) | 2015-08-12 |
| AR072039A1 (es) | 2010-08-04 |
| RU2010129429A (ru) | 2012-01-27 |
| AU2008341542B2 (en) | 2014-12-04 |
| NZ585622A (en) | 2012-10-26 |
| CL2008003784A1 (es) | 2009-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091109A1 (es) | Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c | |
| PE20141787A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| PE20181176A1 (es) | Composiciones biofarmaceuticas | |
| PE20140004A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| AR055191A1 (es) | Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| PE20110821A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina | |
| AU2012249274A8 (en) | Neutralizing antibodies to Nipah and Hendra virus | |
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| PE20121561A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
| EA201290370A1 (ru) | Антитела против flt3 и способы их применения | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
| NZ578844A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| NZ595792A (en) | Antibodies specific to cadherin-17 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |